A New Beginning for our 100- year journey
Our pioneering ideas create a new future for the pharmaceutical industry.
300억
04.2020
Changed our company name to inno.N, marking a new beginning of our journey to become a leading global pharmaceutical industry.
2020
02.2020
Launched the K-CAB.
Achieved revenue of 35.9 billion won within just 11 months.
P-CAB MEGA HIT
2019
A New Beginning
We found our way to more creations.
11.2019
Received ‘ISO 37001’Certification of Global
Anti-Corruption Management System Established the industry’s largest corporate compliance policies.
11.2019
Launched tablet-form CONDITION
CONDITION
INNOVATION
03.2019
Launched Korea's 30th new drug K-CAB.
P-CAB NEW HIT
2018
A New Beginning
07.2018
‘K-CAB‘Tab. (Ingredient name: Tegoprazan), Successfully in-house developed a new drug for gastroesophageal reflux disease, licensed by the Ministry of Food and Drug Safety
Korea’s No.30 New Drug
A NEW BEGINNING
OF P-CAB
01.2018
Achieved 'AA' rating for the Corporate Compliance Program
Out-licensed the second-generation EPO 'CJ-40001'
(a renal anemia treatment) technology to NCPC GeneTech in China
BUILDING NEW
COMPANY
2017
A great leap towards the global market
inno.N aspires to reach beyond Korea to the global market
09.2017
Out-licensed the second-generation EPO 'CJ-40001
(a renal anemia treatment) technology to YL Biologics in Japan
05.2017
Opened inno.N’s representative office in Vietnam (as of May 1)
04.2017
The foundation’s third-year anniversary
The 2nd Self-Compliance Day
03.2017
Signed a MOU for 2017 Volunteer Work with Seoul Volunteer Center
2016
Secure the future’s innovative technology through Open Innovation.
Reached KRW 400 billion in sales
12.2016
SeokHee KANG (CEO of inno.N) was appointed as Self Compliance Manager
09.2016
Hosted the R&D Open Innovation Forum, attended by multiple business ventures from the U.S and Europe
Launched Korea’s first fixed-dose combination IMD for hypertension, ‘MACHKHAN'
08.2016
Launched LUKIO
Held the launch event of the fixed-dose combination IMD for hypertension, ‘MACHKHAN’
Signed a MOU with Seoul Voluntary Center for Employees & Executives Voluntary Work
2016.7
Launched the new version of HUTGAESOO
2016.4
Hosted the R&D Open Innovation Forum with many business ventures from the U.S and Japan
2016.4
The foundation’s second-year anniversary of foundation
Established Self Compliance Day (4.1)
2ND ANNIVERSARY
2016.3
Released the first TV Advertisement for ‘CONDITION’ in Vietnam
2015
2015.10
Developed a new treatment for GERD ˝CJ-12420(Tegoprazan)˝, Transferred such a technology to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd
2014
Launched ‘VOGMET’, a fixed-dose combination IMD for diabetes
Established inno.N Corporation
Debuted CONDITION in 3 different countries (China, Vietnam, and Japan)
2012
2012.05
Won the Beautiful Architecture Award for Cheongwon-gun Office for Osong Plant
`HUTGAESOO` became the No.1 dulcis drink in market share (2012. Nielsen Research)
Upgraded `CONDITION` to `HUTGAE CONDITION` in celebration of its 20th anniversary
Reached KRW 400 billion in sales
2011
Launched ‘MOSAONE’, ‘ABELTAN’, and ‘LUKAIR’
2011.12
Anti-hangover drink `CONDITION` was designated as the `global leading product` by the Ministry of Knowledge & Economy'
Launched `CLOSONE`, a fixed-dose combination for antithrombotic therapy
Formed a joint R&D partnership with Bioleaders to develop anti-cancer drugs and vaccines
2010
2010.03
Completed the construction of manufacturing buildings for oral APIs at Daeso Plant
2010.12
Completed the construction of Osong Plant under international standards
Launched `HEPCURE`
Launched `CONDITION HUTGAESOO (Hovenia Dulcis)`, a beverage.
Lead the market with R&D
inno.N became recognized as the trailblazer in Korea’s pharmaceutical industry by means of investment in continuous R&D.
2009
2009.09
Strategic partnership for injectable solution business (Medi Pharma Plan)
Signed a MOU with the Traditional Medicine Center of Chungbuk Technopark to develop therapeutic ingredients and new drugs
Successfully penetrated the CNS market
Formed a co-promotion/marketing alliance on `SINGULAIR` with MSD Korea and launched `LUKAIR`
Launched `HUTGAE CONDITION POWER`
2008
2008.07
Signed a joint-investment agreement with `Neuralstem` (a U.S. based stem-cell company)
Commenced the construction of a globally competitive plant in Osong Bio-Health Science Technopolis (with an investment worth KRW 150 billion)
2007
Reached revenue of KRW 300 billion
2006
2006.08
Acquires and merges with Hanil Pharmaceutical
2003
2003.06
Registered `PSEUDOVACCIN`, a pseudomonas aeruginosa vaccine & Korea`s No.7 new drug
Launched an anti-hyperlipidemic medication `SIMVASTA`(the first generic drug of simvastatin)
NEW
PRODUCTS
2002
Established a hepatitis B vaccine plant and began exporting to Myanmar
Launched `CEFMENOXIME`, a cephalosporin antibiotic (sterile product)
2002
Advanced R&D and overseas business activities by establishing CJ CheilJedang Pharma New Jersey office
Launched `CEFOTIAM`, a cephalosporin antibiotic
Developed a fluid (I.V. solution) stabilization technology and developed multiple applications into current products
2000
2000.02
Established OBU (Oncology Business Unit) and launched the new antiemetic `CAMPTO`, officially expanding the company’s reach to the anticancer medicine marketư
CANCER UNIT
With the launch of home-grown pharmaceutical products, inno.N opens a new chapter in the industry.
inno.N opened its new chapters in business by successfully localizing many drugs while unlocking USD 100 million in exports, the first in the domestic industry to do so.
1990
1999.03
'Epokine' receives the Chang Yeongsil Prize
1999.02
The Daeso Plant receives certification for outstanding compliance with standards for the production and quality management of active pharmaceutical ingredients
(i.e. certification for BGMP, or Bulk Good Manufacturing Practices)
1998
1998.02
'Epokine', a new drug to treat anemia, is launched (the first of its kind in Korea and the third to be launched worldwide)
Reached 1 hundred million dollars in exported revenue, the first in Korea’s pharmaceutical industry to do so and launched a Cepha antibiotic ‘CEFTAZIDIME’.
1997
Co-developed a diagnostic reagent for epidemic hemorrhagic fever using genetic engineering technology with the National Institutes of Health (first in the world)
1997.04
Developed chicken pox vaccine - Launched `LEGIOFREE` (legionella remover)
Received ‘New Technology’ label (KT Label) for `LEGIOFREE`
Won the Prime Minister Award at the Excellent Patent Product Contest for Pseudomonas Aeruginosa vaccine
Launched antidiabetic `BASEN`
1995
1995.09
`CITOPCIN` injectable received “New Technology” label (KT Label) and won Chang Young-sil Award
Developed the world’s first Pseudomonas Aeruginosa vaccine
1993
Launched the cephalosporin antibiotic `CEFTRIAXONE`
Injectable fluids was certified as KGMP (Korea Good Manufacturing Practice)
Hepatitis B vaccine `HEPACCINE-B` was certified by WHO and delivered overseas for use by UN
Reached KRW 100 billion in sales
1992
1992.11
Launched the cephalosporin antibiotic `CEFTRIAXONE`
Injectable fluids was certified as KGMP (Korea Good Manufacturing Practice)
1992.05
Hepatitis B vaccine `HEPACCINE-B` was certified by WHO and delivered overseas for use by UN
1991
Initiated the production of `7-ACA`, API for Cepha antibiotics
1990
Completed the construction of the manufacturing plant (Daeso Plant) for APIs
FACTORY
DAESO
The beginning of our journey to create a healthier world
inno.N started as Pharmaceutical BU of CJ CheilJedang Corp. in 1984.
1986
1986.12
The Icheon Plant completes its construction
1985
1985.12
'Hepaxin-B', a vaccine for Hepatitis B is developed using domestic technologies only and launched in the market
1984
1984.06
Acquired Yupung Pharmaceuticals
Started our business in pharmaceuticals and established a research institute
Established a U.S.-based R&D center (ETI)
Developed interferon for human lymphocytic cells